Novo Nordisk agreed to acquire Omeros’ stalled MASP‑3 inhibitor program, paying up to $2.1 billion to pick up the paroxysmal nocturnal hemoglobinuria (PNH) candidate and related rights. The deal transfers development responsibility for a mid‑stage rare‑disease asset that Omeros had paused for funding reasons and positions Novo to initiate a global phase 3 program. Novo Nordisk said it will explore the drug’s use in PNH and other rare blood and kidney disorders, and will assume preparations for a phase 3 program Omeros had planned. The company noted prior phase 2 data showed sustained hemoglobin improvements and prevention of hemolysis, underscoring clinical potential across complement‑mediated diseases. For rare‑disease investors and competitors, the transaction signals renewed big‑pharma appetite for complement pathway assets and underscores Novo Nordisk’s strategic expansion beyond metabolic indications. Regulatory and clinical timelines will be central to assessing value realization from the acquisition.